Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.

Neuro-oncology - 8 Sept 2025

Foltyn-Dumitru Martha, Banan Rouzbeh, Schell Marianne, Mahmutoglu Mustafa Ahmed, Kessler Tobias, Wick Wolfgang, Brugnara Gianluca, Bendszus Martin, Sahm Felix, Vollmuth Philipp

Abstract excerpt

BACKGROUND: Glioblastoma (GB) heterogeneity poses substantial challenges for diagnosis and treatment. Isocitrate dehydrogenase (IDH)-wildtype GB may lack contrast enhancement on MRI and exhibit a "low-grade radiologic appearance" (non-contrast-enhancing [CE] GB), a phenomenon with unclear clinical implications. This study investigates the histopathological and molecular differences and survival outcomes between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Contrast Media

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Prognosis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 40108725
DOI: 10.1093/neuonc/noaf070
PMCID: PMC12417822

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.PMID 40108725Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.Semantic proximity Read ↗

Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

Molecularly diagnosed glioblastoma: clinical presentation and outcomes.Semantic proximity Read ↗

Glioblastoma: Changing concepts in the WHO CNS5 classification.Semantic proximity Read ↗

A clinical evaluation of cystic features in patients with newly diagnosed glioblastoma with IDH-wildtype.Semantic proximity Read ↗

Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.Semantic proximity Read ↗

Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.Semantic proximity Read ↗

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.Semantic proximity Read ↗

Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.Semantic proximity Read ↗

Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.